Filters








212,023 Hits in 5.2 sec

Practical Mutation Testing at Scale [article]

Goran Petrović, Marko Ivanković, Gordon Fraser, René Just
2021 arXiv   pre-print
The traditional approach to mutation testing does not scale to such an environment.  ...  Overall, the proposed approach represents a mutation testing framework that seamlessly integrates into the software development workflow and is applicable up to large-scale industrial settings.  ...  MUTATION TESTING AT GOOGLE Mutation testing at Google faces challenges of scale, both in terms of computation time as well as integration into the developer workflow.  ... 
arXiv:2102.11378v2 fatcat:gewup63vbvgxrl6sblzrjqynhy

Practical Mutation Testing at Scale: A view from Google

Goran Petrovic, Marko Ivankovic, Gordon Fraser, Rene Just
2021 IEEE Transactions on Software Engineering  
The traditional approach to mutation testing does not scale to such an environment; even existing solutions to speed up mutation analysis are insufficient to make it computationally feasible at such a  ...  scale.  ...  MUTATION TESTING AT GOOGLE Mutation testing at Google faces challenges of scale, both in terms of computation time as well as integration into the developer workflow.  ... 
doi:10.1109/tse.2021.3107634 fatcat:ibrysosxmnbr7fjj6u4mpoxlyy

Early Neurodevelopmental Findings Predict School Age Cognitive Abilities in Duchenne Muscular Dystrophy: A Longitudinal Study

Daniela Chieffo, Claudia Brogna, Angela Berardinelli, Grazia D'Angelo, Maria Mallardi, Adele D'Amico, Paolo Alfieri, Eugenio Mercuri, Marika Pane, Ronald Cohn
2015 PLoS ONE  
Methods We performed cognitive tests at school age (mean age 5.7 year ±1.7 SD) (69 months+19 SD) in a cohort of Duchenne boys, previously assessed using the Griffiths scales before the age of 4 years (  ...  When we subdivided the cohort according to site of mutations, there was a difference between boys with mutations upstream exon 44 and those with mutations in exon 44-45 affecting Dp140 on both Developmental  ...  As part of our clinical practice, patients are routinely assessed with ageappropriate neurodevelopmental and, at school age, with cognitive scales.  ... 
doi:10.1371/journal.pone.0133214 pmid:26275215 pmcid:PMC4537199 fatcat:y46egwtdyvaqhg4wkg4we4mf6i

DeepHunter: Hunting Deep Neural Network Defects via Coverage-Guided Fuzzing [article]

Xiaofei Xie, Lei Ma, Felix Juefei-Xu, Hongxu Chen, Minhui Xue, Bo Li, Yang Liu, Jianjun Zhao, Jianxiong Yin, Simon See
2018 arXiv   pre-print
To be scalable towards practical-sized DNNs, DeepHunter maintains multiple tests in a batch, and prioritizes the tests selection based on active feedback.  ...  DeepHunter performs metamorphic mutation to generate new semantically preserved tests, and leverages multiple plugable coverage criteria as feedback to guide the test generation from different perspectives  ...  We are now engaged in new AI development and deployment at an unprecedented speed and scale.  ... 
arXiv:1809.01266v3 fatcat:xyjpjnlvojazvhqv5u6wpod4qu

Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer

Steven J. Katz, Irina Bondarenko, Kevin C. Ward, Ann S. Hamilton, Monica Morrow, Allison W. Kurian, Timothy P. Hofer
2018 JAMA Surgery  
Approximately one-third (34.5% [1350 of 3910] of patients had an elevated risk of mutation carriage, and 27.0% (1056 of 3910) overall had genetic testing.  ...  -77.2%) if she saw a surgeon at the 95th percentile.  ...  We next considered surgeon factors in addition to our Tendency to Test Scale (eg, years in practice, sex, and annual patient volume) by examining the univariate association of several surgeon-level practice  ... 
doi:10.1001/jamasurg.2018.2001 pmid:29971344 pmcid:PMC6233787 fatcat:f4xfk72i4nb7tmzxvz4asonmsm

Does mutation testing improve testing practices? [article]

Goran Petrović, Marko Ivanković, Gordon Fraser, René Just
2021 arXiv   pre-print
Despite the obvious advantages of mutation testing, it is not yet well established in practice. Until recently, mutation testing tools and techniques simply did not scale to complex systems.  ...  Although they now do scale, a remaining obstacle is lack of evidence that writing tests for mutants actually improves test quality.  ...  In line with prior results, our mutation approach samples very few mutants to make mutation testing applicable at scale.  ... 
arXiv:2103.07189v1 fatcat:lilhxamgtfeehnkxvv3hs3b7ka

Parkinson's disease with a homozygous PARK7 mutation and clinical onset at the age of five years

Aline Delva, Valérie Race, Elizabet Boon, Koen Van Laere, Wim Vandenberghe
2020 Movement Disorders Clinical Practice  
All videos show the patient off medication at the age of 31 years, after approximately 26 years of disease evolution.  ...  Relevant disclosures and conflicts of interest are listed at the end of this article. [Corrections added on Dec 18, 2020, after first online publication: Video images included.]  ...  Olfactory testing has previously been reported in only 2 patients with PD with PARK7 mutations.  ... 
doi:10.1002/mdc3.13114 pmid:34869787 pmcid:PMC8607977 fatcat:wzfxd55re5aotengo7l2jfgooe

EFNS guidelines on diagnosis and treatment of primary dystonias

A. Albanese, F. Asmus, K. P. Bhatia, A. E. Elia, B. Elibol, G. Filippini, T. Gasser, J. K. Krauss, N. Nardocci, A. Newton, J. Valls-Solé
2010 European Journal of Neurology  
Individuals with early-onset myoclonus should be tested for mutations in the DYT11 gene.  ...  Assessment should be performed using a validated rating scale for dystonia. Genetic testing may be performed after establishing the clinical diagnosis.  ...  Individuals with early-onset myoclonus should be tested for mutations in the DYT11 gene.  ... 
doi:10.1111/j.1468-1331.2010.03042.x pmid:20482602 fatcat:rbtle4deujao7mte3rnaes5rhu

Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA

Joseph E. Jacher, Lisa J. Martin, Wendy K. Chung, James E. Loyd, William C. Nichols
2017 Pulmonary Circulation  
Identifying those at risk through early interventions, such as genetic testing, may mitigate disease course.  ...  Current practice guidelines recommend genetic counseling and offering genetic testing to individuals with heritable PAH, idiopathic PAH, and their family members.  ...  A Likert scale is a common tool used to evaluate variables that are continuous in nature. 29 In this study, the Likert scale questions were designed to quantify the participants' attitudes and practices  ... 
doi:10.1177/2045893217700156 pmid:28597770 pmcid:PMC5467928 fatcat:c4dakhbj4fcwvliv3ulzhklajm

A stringent test for hydrophobicity scales: Two proteins with 88% sequence identity but different structure and function

A. E. Kister, J. C. Phillips
2008 Proceedings of the National Academy of Sciences of the United States of America  
This example explains why protein structure prediction is so challenging, and it provides a severe test for the accuracy and content of hydrophobicity scales.  ...  In practice, however, attempts to develop hydrophobicity scales (for example, compatible with classical force fields (CFF) in calculating the energetics of protein folding) have encountered many difficulties  ...  These tests are demanding, and it is extremely unlikely that an unsound scale could pass them (8) .  ... 
doi:10.1073/pnas.0803264105 pmid:18591657 pmcid:PMC2453729 fatcat:rfz526hkqzenvbwibicmdte77a

Current practices and guidelines for clinical next-generation sequencing oncology testing

Samuel P Strom
2016 Cancer Biology and Medicine  
assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.  ...  This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for  ...  Thus the current common practice is to use the results of genome-wide sequencing as a resource to inform clinical test development.  ... 
doi:10.28092/j.issn.2095-3941.2016.0004 pmid:27144058 pmcid:PMC4850126 fatcat:b43lnf2bgvbahfajg5cubtlile

Too Many Referrals of Low-Risk Women for BRCA1/2 Genetic Services by Family Physicians

D. B. White, V. L. Bonham, J. Jenkins, N. Stevens, C. M. McBride
2008 Cancer Epidemiology, Biomarkers and Prevention  
Family physicians (n = 284) completed a Web-based survey in 2006 to assess their attitudes and practices related to the use of genetics in their clinical practice.  ...  Family physicians regarded it unlikely that the patient carried a mutation, but 65% of family physicians believed that if they refused to refer for genetic services it would harm their relationship with  ...  We thank the American Academy of Family Physicians for partnering with us in this research; Cristopher Price and Amanda Parsad for their statistical expertise; the team led by Donald Dorfman at Esprit  ... 
doi:10.1158/1055-9965.epi-07-2879 pmid:18990739 pmcid:PMC2772063 fatcat:y7rfq5nbhfhorivor5l7jva3ke

Current practices and guidelines for clinical next-generation sequencing oncology testing

Samuel P. Strom, Samuel P. Strom
2016 Cancer Biology and Medicine  
assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.  ...  This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for  ...  Thus the current common practice is to use the results of genome-wide sequencing as a resource to inform clinical test development.  ... 
doi:10.20892/j.issn.2095-3941.2016.0004 fatcat:ynxdcaxldbaqhkcbwfygsxnp2e

Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling

Jean Jenkins, Kathleen A Calzone, Eileen Dimond, David J Liewehr, Seth M Steinberg, Oxana Jourkiv, Pam Klein, Peter W Soballe, Sheila A Prindiville, Ilan R Kirsch
2007 Genetics in Medicine  
Data from the State-Trait Anxiety Inventory and the Psychological General Well-Being index were collected at baseline and then again at 1 week and 3 months after disclosure of test results.  ...  At 1 week, participants were asked their preferred method of result disclosure.  ...  Genetic test results Twenty seven (26%) deleterious mutations, 19 mutations in BRCA1, and 8 mutations in BRCA2 were detected.  ... 
doi:10.1097/gim.0b013e31812e6220 pmid:17700386 fatcat:7mycweq3iveutopamnhj6sol6i

Letter by Benbir et al Regarding Article, "The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Scale. A Screening Tool to Select Patients for NOTCH3 Gene Analysis"

G. Benbir, B. Ince, A. Siva, O. Uyguner
2013 Stroke  
Include a completed copyright transfer agreement form (available online at  ...  is considerably important from practical point of view.  ...  On this context, we believe this newly described CADASIL scale would provide a better selection of patients and increase the feasibility of genetic testing. Disclosures None.  ... 
doi:10.1161/strokeaha.111.000164 pmid:23404717 fatcat:hxalhlwdhbgxdcp6y7kaw3uknq
« Previous Showing results 1 — 15 out of 212,023 results